Health & Environmental Research Online (HERO)


Print Feedback Export to File
7425985 
Journal Article 
Radiopharmaceuticals for Prostate Cancer 
Donnelly, AnnE; Hurwitz, MD; , 
2021 
Springer International Publishing 
Cham 
Chemotherapy and Immunotherapy in Urologic Oncology 
119-132 
A high percentage of patients with metastatic prostate cancer have evidence of bone metastases that are either symptomatic or visible on radiographic imaging (Roodman, N Engl J Med 350:1655–1664, 2004). Patients with osteoblastic metastatic disease often experience pain and have a high risk for pathologic fractures due to compromise of the affected bone. Therefore, treatment of the pain and complications from bone metastases can become complicated and costly (Roodman, N Engl J Med 350:1655–1664, 2004). Radiopharmaceuticals can be used in the treatment of bone metastases from prostate cancer. Strontium-89 and samarium-153 have been approved for the palliative treatment of bone metastases to decrease pain but have not been shown to have survival benefit. Radium-223 has been shown to be effective for pain control, as well as providing a survival benefit, for patients with castrate-resistant prostate cancer involving bone without visceral metastatic disease. This chapter discusses the characteristics of each radiopharmaceutical agent, as well as important information for managing patients undergoing treatment.